Radioimmunotherapy-based conditioning for hematopoietic stem cell transplantation: Another step forward

Jenq, 2010, Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer, Nat Rev Cancer, 10, 213, 10.1038/nrc2804 Gooley, 2010, Reduced mortality after allogeneic hematopoietic-cell transplantation, N Engl J Med, 363, 2091, 10.1056/NEJMoa1004383 Clift, 1990, Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens, Blood, 76, 1867, 10.1182/blood.V76.9.1867.1867 Clift, 1991, Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens, Blood, 77, 1660, 10.1182/blood.V77.8.1660.1660 Duval, 2010, Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure, J Clin Oncol, 28, 3730, 10.1200/JCO.2010.28.8852 Larson, 2015, Radioimmunotherapy of human tumours, Nat Rev Cancer, 15, 347, 10.1038/nrc3925 Marks, 2006, A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission, Biol Blood Marrow Transplant, 12, 438, 10.1016/j.bbmt.2005.12.029 Derenzini, 2013, Collection of hematopoietic stem cells after previous radioimmunotherapy is feasible and does not impair engraftment after autologous stem cell transplantation in follicular lymphoma, Biol Blood Marrow Transplant, 19, 1695, 10.1016/j.bbmt.2013.09.004 Rao, 2005, Radioimmunotherapy for non-Hodgkin's lymphoma, Clin Med Res, 3, 157, 10.3121/cmr.3.3.157 Stein, 2003, Improved iodine radiolabels for monoclonal antibody therapy, Cancer Res, 63, 111 Press, 1996, Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells, Cancer Res, 56, 2123 Kassis, 2005, Radiobiologic principles in radionuclide therapy, J Nucl Med, 46, 4S Shen, 2005, Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry, J Nucl Med, 46, 1034 Park, 2010, Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease, Blood, 116, 4231, 10.1182/blood-2010-05-282327 Zalutsky, 2007, Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies, Nucl Med Biol, 34, 779, 10.1016/j.nucmedbio.2007.03.007 Zalutsky, 2006, Targeted alpha-particle therapy of microscopic disease: providing a further rationale for clinical investigation, J Nucl Med, 47, 1238 Jurcic, 2002, Targeted alpha particle immunotherapy for myeloid leukemia, Blood, 100, 1233, 10.1182/blood.V100.4.1233.h81602001233_1233_1239 Ding, 2012, Image guided biodistribution and pharmacokinetic studies of theranostics, Theranostics, 2, 1040, 10.7150/thno.4652 Press, 1993, Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support, N Engl J Med, 329, 1219, 10.1056/NEJM199310213291702 Press, 1995, Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas, Lancet (London, Engl), 346, 336, 10.1016/S0140-6736(95)92225-3 Liu, 1998, Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue, J Clin Oncol, 16, 3270, 10.1200/JCO.1998.16.10.3270 Gopal, 2003, High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis, Blood, 102, 2351, 10.1182/blood-2003-02-0622 Winter, 2009, Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma, J Clin Oncol, 27, 1653, 10.1200/JCO.2008.19.2245 Nademanee, 2005, A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma, Blood, 106, 2896, 10.1182/blood-2005-03-1310 Press, 2000, A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas, Blood, 96, 2934, 10.1182/blood.V96.9.2934 Decaudin, 2011, (90)Y ibritumomab tiuxetan (zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study, Clin Lymphoma Myeloma Leuk, 11, 212, 10.1016/j.clml.2011.03.007 Vose, 2005, Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma, J Clin Oncol, 23, 461, 10.1200/JCO.2005.05.117 Mei, 2014, Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen, Biol Blood Marrow Transplant, 20, 2072, 10.1016/j.bbmt.2014.07.028 Briones, 2014, Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial, Haematologica, 99, 10.3324/haematol.2013.093450 Fruchart, 2014, Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma, Biol Blood Marrow Transplant, 20, 1905, 10.1016/j.bbmt.2014.07.024 Krishnan, 2008, Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma, J Clin Oncol, 26, 90, 10.1200/JCO.2007.11.9248 Shimoni, 2007, Yttrium-90-ibritumomab tiuxetan (zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma, Exp Hematol, 35, 534, 10.1016/j.exphem.2007.01.043 Vose, 2013, Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT C, J Clin Oncol, 31, 1662, 10.1200/JCO.2012.45.9453 Johnson, 2000, Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas, Int J Cancer, 85, 104, 10.1002/(SICI)1097-0215(20000101)85:1<104::AID-IJC19>3.0.CO;2-G Gopal, 2006, Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy, Biol Blood Marrow Transplant, 12, 697, 10.1016/j.bbmt.2006.03.014 Begleiter, 1988, Enhanced cytotoxicity and inhibition of DNA damage repair in irradiated murine L5178Y lymphoblasts and human chronic lymphocytic leukemia cells treated with 2′-deoxycoformycin and deoxyadenosine in vitro, Cancer Res, 48, 3981 Gopal, 2014, Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age≥60years with B cell lymphoma, Biol Blood Marrow Transplant, 20, 770, 10.1016/j.bbmt.2014.02.004 Cassaday, 2015, High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma, Br J Haematol, 10.1111/bjh.13773 Berger, 2015, Zevalin and BEAM (Z-BEAM) versus rituximab and BEAM (R-BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma, Hematol Oncol Kolstad, 2014, Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma, Blood, 123, 2953, 10.1182/blood-2013-12-541953 Devizzi, 2008, High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation, J Clin Oncol, 26, 5175, 10.1200/JCO.2008.16.8294 Devizzi, 2013, Long-term results of autologous hematopoietic stem-cell transplantation after high-dose 90Y-ibritumomab tiuxetan for patients with poor-risk non-Hodgkin lymphoma not eligible for high-dose BEAM, J Clin Oncol, 31, 2974, 10.1200/JCO.2013.50.2922 Gribben, 2005, Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia, Blood, 106, 4389, 10.1182/blood-2005-05-1778 Doocey, 2005, Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma, Br J Haematol, 131, 223, 10.1111/j.1365-2141.2005.05755.x Peggs, 2005, The role of allogeneic transplantation in non-Hodgkin's lymphoma, Br J Haematol, 128, 153, 10.1111/j.1365-2141.2004.05251.x Haas, 2005, Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients, Eur J Cancer, 41, 1724, 10.1016/j.ejca.2005.04.033 Fisher, 2005, Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas, J Clin Oncol, 23, 7565, 10.1200/JCO.2004.00.9217 Shimoni, 2008, Ibritumomab tiuxetan (zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma, Bone Marrow Transplant, 41, 355, 10.1038/sj.bmt.1705919 Bethge, 2010, Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study, Blood, 116, 1795, 10.1182/blood-2010-02-270538 Gopal, 2011, 90Y-ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma, Blood, 118, 1132, 10.1182/blood-2010-12-324392 Khouri, 2012, Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results, Blood, 119, 6373, 10.1182/blood-2012-03-417808 Cassaday, 2015, Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation, Biol Blood Marrow Transplant, 21, 281, 10.1016/j.bbmt.2014.10.024 Dinndorf, 1986, Expression of normal myeloid-associated antigens by acute leukemia cells, Blood, 67, 1048, 10.1182/blood.V67.4.1048.1048 Hernández-Caselles, 2006, A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing, J Leukoc Biol, 79, 46, 10.1189/jlb.0205096 Scheinberg, 1991, A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide, J Clin Oncol, 9, 478, 10.1200/JCO.1991.9.3.478 Caron, 1994, A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity, Blood, 83, 1760, 10.1182/blood.V83.7.1760.1760 Caron, 1992, Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies, Cancer Res, 52, 6761 Schwartz, 1993, Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias, J Clin Oncol, 11, 294, 10.1200/JCO.1993.11.2.294 Burke, 2003, Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias, Bone Marrow Transplant, 32, 549, 10.1038/sj.bmt.1704201 Appelbaum, 1992, The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia, Transplantation, 54, 829, 10.1097/00007890-199211000-00012 Jurcic, 2000, Potential for myeloablation with yttrium-90-HuM195 (anti-CD33) in myeloid leukemia, Proc Am Soc Clin Oncol, 19, 8a Ravandi, 2013, Phase I trial of the targeted alpha-particle nano-generator actinium-225 (225Ac)-lintuzumab (anti-CD33) in combination with low-dose cytarabine (LDAC) for older patients with untreated acute myeloid leukemia (AML), Blood, 122, 1460, 10.1182/blood.V122.21.1460.1460 Rosenblat, 2010, Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia, Clin Cancer Res, 16, 5303, 10.1158/1078-0432.CCR-10-0382 Nakano, 1990, Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines, Acta Pathol Jpn, 40, 107 Dahlke, 2004, The biology of CD45 and its use as a therapeutic target, Leuk Lymphoma, 45, 229, 10.1080/1042819031000151932 Kumar, 2005, CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations, Leukemia, 19, 1466, 10.1038/sj.leu.2403823 van der Jagt, 1992, Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model, Cancer Res, 52, 89 Matthews, 1995, Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation, Blood, 85, 1122, 10.1182/blood.V85.4.1122.bloodjournal8541122 Matthews, 1999, Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome, Blood, 94, 1237, 10.1182/blood.V94.4.1237 Mawad, 2014, Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome, Biol Blood Marrow Transplant, 20, 1363, 10.1016/j.bbmt.2014.05.014 Pagel, 2006, 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission, Blood, 107, 2184, 10.1182/blood-2005-06-2317 Pagel, 2009, Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome, Blood, 114, 5444, 10.1182/blood-2009-03-213298 Orozco, 2016, Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment, Blood, 127, 352, 10.1182/blood-2014-12-617019 Orozco, 2013, Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model, Blood, 121, 3759, 10.1182/blood-2012-11-467035 Chen, 2012, Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation, Blood, 119, 1130, 10.1182/blood-2011-09-380436 Bunjes, 2001, Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study, Blood, 98, 565, 10.1182/blood.V98.3.565 Bunjes, 2002, 188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia, Leuk Lymphoma, 43, 2125, 10.1080/1042819021000033015 Lauter, 2010, 188Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation, Br J Haematol, 148, 910, 10.1111/j.1365-2141.2009.08025.x Schneider, 2015, Reduced-intensity conditioning combined with (188)rhenium radioimmunotherapy before allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia: the role of in vivo T cell depletion, Biol Blood Marrow Transplant, 21, 1754, 10.1016/j.bbmt.2015.05.012 Zenz, 2006, Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study, Haematologica, 91, 285 Zenz, 2006, Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation, J Nucl Med, 47, 278 Koenecke, 2008, Radioimmunotherapy with [188Re]-labelled anti-CD66 antibody in the conditioning for allogeneic stem cell transplantation for high-risk acute myeloid leukemia, Int J Hematol, 87, 414, 10.1007/s12185-008-0043-1 Orchard, 2006, Targeted radiotherapy in the conditioning prior to haematopoietic stem cell transplantation: Results of a phase I trial using an yttrium-90-labelled anti-CD66 murine monoclonal antibody demonstrating consistently high BM uptake, Biol Blood Marrow Transplant, 12, 0, 10.1016/j.bbmt.2005.11.036 Attal, 2012, Lenalidomide maintenance after stem-cell transplantation for multiple myeloma, N Engl J Med, 366, 1782, 10.1056/NEJMoa1114138 Moreau, 2002, Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Fra, Blood, 99, 731, 10.1182/blood.V99.3.731 Gouard, 2014, Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and melphalan chemotherapy, Nucl Med Biol, 41, e30, 10.1016/j.nucmedbio.2014.02.008 Chérel, 2013, 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma, J Nucl Med, 54, 1597, 10.2967/jnumed.112.111997 Supiot, 2002, Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma, Cancer, 94, 1202, 10.1002/cncr.10286 Couturier, 1999, Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma, Clin Cancer Res, 5, 3165s Josef, 2010, Expression of CD66 in non-Hodgkin lymphomas and multiple myeloma, Eur J Haematol, 85, 496, 10.1111/j.1600-0609.2010.01529.x Lee, 2010, CD66a (CEACAM1) is the only CD66 variant expressed on the surface of plasma cells in multiple myeloma: a refined target for radiotherapy trials?, Br J Haematol, 149, 795, 10.1111/j.1365-2141.2010.08100.x Bayouth, 1995, Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma, J Nucl Med, 36, 730 Rajendran, 2002, High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation, J Nucl Med, 43, 1383 Giralt, 2003, 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials, Blood, 102, 2684, 10.1182/blood-2002-10-3250 Rousseau, 2012, Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients, Tumour Biol, 33, 679, 10.1007/s13277-012-0362-y Jaggi, 2005, Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters, J Am Soc Nephrol, 16, 2677, 10.1681/ASN.2004110945 Jaggi, 2005, Efforts to control the errant products of a targeted in vivo generator, Cancer Res, 65, 4888, 10.1158/0008-5472.CAN-04-3096 Jaggi, 2006, Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys, Int J Radiat Oncol Biol Phys, 64, 1503, 10.1016/j.ijrobp.2005.11.036 Lin, 2006, A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies, Cancer Res, 66, 3884, 10.1158/0008-5472.CAN-05-3443 Yao, 2004, Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N′,N″,N″′-tetraacetic acid-biotin, Clin Cancer Res, 10, 3137, 10.1158/1078-0432.CCR-03-0171 Zhang, 2003, Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts, Proc Natl Acad Sci U S A, 100, 1891, 10.1073/pnas.0437788100 Pagel, 2008, Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy, Blood, 111, 2261, 10.1182/blood-2007-06-097451 Pagel, 2011, Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model, Blood, 118, 703, 10.1182/blood-2011-04-347039 Goldenberg, 2006, Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy, J Clin Oncol, 24, 823, 10.1200/JCO.2005.03.8471